NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
Clinical Trials
616 trialsNCT06465316 2026-03-18
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03798678 2026-03-17
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07477587 2026-03-17
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT03091257 2026-03-13
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04108195 2026-03-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT04722146 2026-03-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04960579 2026-03-13
MM
Poseida Therapeutics, Inc.
Phase 1 Recruiting
NCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05652335 2026-03-13
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05862012 2026-03-13
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Ichnos Sciences SA
Phase 1 Recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06425991 2026-03-13
MajesTEC-10
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06604715 2026-03-13
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06768489 2026-03-13
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06185751 2026-03-11
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Washington University School of Medicine
Phase 1 Recruiting
NCT06223516 2026-03-11
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT06623630 2026-03-11
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
Phase 1 Recruiting
NCT03984097 2026-03-10
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Active not recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06375044 2026-03-06
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05927571 2026-03-05
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07073547 2026-03-05
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
AstraZeneca
Phase 1 Recruiting
NCT07280013 2026-03-05
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
C4 Therapeutics, Inc.
Phase 1 Recruiting
NCT03070327 2026-03-04
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03741127 2026-03-04
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05887167 2026-03-04
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Phase 1 Recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02291848 2026-02-25
TACTAM
Baylor College of Medicine
Phase 1 Recruiting
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07082270 2026-02-19
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Not yet recruiting
NCT06121843 2026-02-18
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT05391750 2026-02-17
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Phase 1 Active not recruiting
NCT05646836 2026-02-17
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Active not recruiting
NCT07333261 2026-02-13
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
University of Alabama at Birmingham
Phase 1 Recruiting
NCT07409246 2026-02-13
A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1 Not yet recruiting
NCT05650632 2026-02-12
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT07407010 2026-02-12
CM336-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT04322292 2026-02-11
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05651932 2026-02-10
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT07400744 2026-02-10
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT04674813 2026-02-09
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT03275103 2026-02-05
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Completed
NCT06215118 2026-02-05
MagnetisMM-30
Pfizer
Phase 1 Recruiting
NCT06574568 2026-02-05
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1 Recruiting